RAPT Therapeutics, Inc. (RAPT) Earnings History
Annual and quarterly earnings data from 2017 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 100.0% | -5618.5% | -5490.4% |
| 2021 | 100.0% | -1815.1% | -1814.9% |
| 2020 | 100.0% | -1055.4% | -1049.0% |
Download Data
Export RAPT earnings history in CSV or JSON format
Free sign-in required to download data
RAPT Therapeutics, Inc. (RAPT) Earnings Overview
As of February 28, 2026, RAPT Therapeutics, Inc. (RAPT) reported trailing twelve-month net income of -$106M, reflecting -0.0% year-over-year growth. The company earned $-3.92 per diluted share over the past four quarters.
Looking at the long-term picture, RAPT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$29M in fiscal 2017.
RAPT Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), RAPT has comparable earnings metrics. Compare RAPT vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$130M | -11.2% | -$136M | $-25.49 | - | - |
| 2023 | -$117M | -39.3% | -$127M | $-24.37 | - | - |
| 2022 | -$84M | -21.1% | -$86M | $-20.61 | -5490.4% | -5618.5% |
| 2021 | -$69M | -30.8% | -$69M | $-20.21 | -1814.9% | -1815.1% |
| 2020 | -$53M | -23.0% | -$53M | $-17.53 | -1049.0% | -1055.4% |
| 2019 | -$43M | -19.0% | -$44M | $-15.75 | - | - |
| 2018 | -$36M | -24.2% | -$37M | $-13.59 | - | - |
| 2017 | -$29M | - | -$29M | $-10.95 | - | - |
See RAPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RAPT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RAPT vs AGIO
See how RAPT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RAPT growing earnings?
RAPT TTM EPS: $-3.92. Net income: $-106M. Earnings growth: -0.0%.
What are RAPT's profit margins?
RAPT Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are RAPT's earnings?
RAPT earnings data spans 2017-2024. The current earnings trend is -0.0% YoY. Historical data enables comparison across business cycles.